Tetra's Alzheimer's Drug Improves Language, Learning in Fragile X Syndrome

An investigational Alzheimer's disease (AD) drug from Tetra Therapeutics appeared to improve language ability and learning in adults with Fragile X Syndrome, according to a new study reported in Nature Medicine.

The company's AD drug, BPN14770, is a novel treatment designed to selectively inhibit phosphodiesterase-4D. In turn, this inhibition increases levels of cAMP, an essential signaling molecule found in the brain.